These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30216393)

  • 1. Buprenorphine to treat opioid use disorder: A practical guide.
    Nissly T; Levy R
    J Fam Pract; 2018 Jun; 67(9):544-548. PubMed ID: 30216393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 3. [Better efficacy of buprenorphine and methadone in opioid dependence. Requirements for abstinence from non-opioids before starting treatment paid off].
    Hoffmann O; Frisell F; Ljungberg T
    Lakartidningen; 2014 Jan 29-Feb 4; 111(5):147-9. PubMed ID: 24624763
    [No Abstract]   [Full Text] [Related]  

  • 4. Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study.
    Mullins N; Galvin SL; Ramage M; Gannon M; Lorenz K; Sager B; Coulson CC
    J Addict Med; 2020; 14(3):185-192. PubMed ID: 31567599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Should high-dose buprenorphine be withdrawn from the French market?].
    Rolland B; Muyssen A; Danel T; Cottencin O
    Rev Epidemiol Sante Publique; 2013 Apr; 61(2):91-2. PubMed ID: 23489947
    [No Abstract]   [Full Text] [Related]  

  • 6. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 10. Overcoming Barriers to Treatment of Opioid Use Disorder.
    Olsen Y; Fitzgerald RM; Wakeman SE
    JAMA; 2021 Mar; 325(12):1149-1150. PubMed ID: 33630021
    [No Abstract]   [Full Text] [Related]  

  • 11. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removing One Barrier to Opioid Use Disorder Treatment: Is It Enough?
    Weimer MB; Wakeman SE; Saitz R
    JAMA; 2021 Mar; 325(12):1147-1148. PubMed ID: 33630020
    [No Abstract]   [Full Text] [Related]  

  • 13. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period.
    Lembke A; Ottestad E; Schmiesing C
    Pain Med; 2019 Mar; 20(3):425-428. PubMed ID: 29452378
    [No Abstract]   [Full Text] [Related]  

  • 14. The occasional treatment of opioid use disorder.
    Robinson A; Carlson RF; Kelly L
    Can J Rural Med; 2017; 22(2):69-75. PubMed ID: 28441131
    [No Abstract]   [Full Text] [Related]  

  • 15. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 16. ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.
    Marino R; Perrone J; Nelson LS; Wiegand TJ; Schwarz ES; Wax PM; Stolbach AI
    J Med Toxicol; 2019 Oct; 15(4):307-309. PubMed ID: 31414402
    [No Abstract]   [Full Text] [Related]  

  • 17. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 18. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 19. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.